Tue, May 22, 2012 - Page 9 News List

Seizing the moment to ease the ills of global health

More government support for drug research and sharing of scientific knowledge would remedy a long-standing inequity in healthcare

By Joseph Stiglitz

Illustration: Yusha

Every year, millions of people die from preventable and treatable diseases, especially in poor countries. In many cases, lifesaving medicines can be cheaply mass produced, but are sold at prices that block access to those who need them. Many die simply because there are no cures or vaccines, because so little of the world’s valuable research talent and limited resources are devoted to addressing the diseases of the poor.

This state of affairs represents a failure of economics and law that urgently needs to be corrected. The good news is that there are now opportunities for change, most promisingly through an international effort headed by the WHO that would begin to fix the broken intellectual property regime that is holding back the development and availability of cheap drugs.

Two main problems limit the availability of medicines today. One is that they are very costly; or, more accurately, the price charged for them is very high, though the cost of producing them is but a fraction of that amount. Second, drug development is geared toward maximizing profit, not social benefit, which skews efforts directed at the creation of medicines that are essential to human welfare. Because the poor have so little money to spend, drug companies, under current arrangements, have little incentive to do research on the diseases that afflict them.

It does not have to be this way. Drug companies say that high prices are necessary to fund research and development. However, in the US, it is actually the government that finances most health-related research and development — directly, through public support (National Institutes of Health, National Science Foundation), and indirectly, through public purchases of medicine, both in the Medicare and Medicaid programs. Even the part that is not government-financed is not a conventional market; most individuals’ purchases of prescription medicines are covered by insurance.

Government finances healthcare research because improved medicines are a public good. The resulting knowledge benefits everyone by stopping epidemics and limiting the economic and human toll of widespread illness. Efficiency requires sharing research as widely as possible as soon as it is available. Thomas Jefferson compared knowledge to candles: When one is used to light another, it does not diminish the light of the first. On the contrary, everything becomes brighter.

Yet, in the US and most of the world, drug prices are still exorbitant and the spread of knowledge is tightly limited. That is because we have created a patent system that gives innovators a temporary monopoly over what they create, which encourages them to hoard their knowledge, lest they help a competitor.

While this system does provide incentives for certain kinds of research by making innovation profitable, it allows drug companies to drive up prices, and the incentives do not necessarily correspond to social returns. In the healthcare sector, it may be more profitable to devote research to a “me-too” drug than to the development of a treatment that really makes a difference. The patent system may even have adverse effects on innovation, because, while the most important input into any research is prior ideas, the patent system encourages secrecy.

A solution to both high prices and misdirected research is to replace the current model with a government-supported prize fund. With a prize system, innovators are rewarded for new knowledge, but they do not retain a monopoly on its use. That way, the power of competitive markets can ensure that, once a drug is developed, it is made available at the lowest possible price — not at an inflated monopoly price.

This story has been viewed 1607 times.
TOP top